The estimated Net Worth of James L Tyree is at least $21.2 Миллион dollars as of 14 March 2024. Mr. Tyree owns over 10,251 units of ChemoCentryx Inc stock worth over $9,787,169 and over the last 20 years he sold CCXI stock worth over $11,162,591. In addition, he makes $259,401 as Independent Director at ChemoCentryx Inc.
James has made over 37 trades of the ChemoCentryx Inc stock since 2006, according to the Form 4 filled with the SEC. Most recently he sold 10,251 units of CCXI stock worth $11,481 on 14 March 2024.
The largest trade he's ever made was exercising 98,831 units of ChemoCentryx Inc stock on 2 February 2009 worth over $4,548,203. On average, James trades about 11,117 units every 110 days since 2005. As of 14 March 2024 he still owns at least 188,251 units of ChemoCentryx Inc stock.
You can see the complete history of Mr. Tyree stock trades at the bottom of the page.
James L. Tyree serves as Independent Director of the Company. Mr. Tyree has served as co-founder, chairman and managing partner of Tyree & D’Angelo Partners, a private equity investment firm. Prior to founding Tyree & D’Angelo Partners, Mr. Tyree was Executive Vice President and President of Abbott Biotech Ventures, a subsidiary of Abbott Laboratories focused on investments in early stage biotechnology companies. Prior to that, Mr. Tyree held numerous executive positions at Abbott, including Executive Vice President Global Pharmaceuticals, Senior Vice President Global Nutrition, Corporate Vice President Pharmaceutical and Nutritional Products Group Business Development and Divisional Vice President and General Manager, Japan. Prior to rejoining Abbott in 1997, Mr. Tyree was the President of SUGEN, Inc., and held management positions in Bristol-Myers Squibb, Pfizer and Abbott. Mr. Tyree currently serves as a director of Assertio Therapeutics, Inc. Mr. Tyree earned Bachelor’s Degrees in Psychology and Forensic Studies and a Master’s Degree in Business Administration from Indiana University.
As the Independent Director of ChemoCentryx Inc, the total compensation of James Tyree at ChemoCentryx Inc is $259,401. There are 7 executives at ChemoCentryx Inc getting paid more, with Thomas Schall having the highest compensation of $3,341,860.
James Tyree is 67, he's been the Independent Director of ChemoCentryx Inc since 2012. There are 2 older and 11 younger executives at ChemoCentryx Inc. The oldest executive at ChemoCentryx Inc is Henry McKinnell, 77, who is the Independent Director.
James's mailing address filed with the SEC is ASSERTIO HOLDINGS, INC., 100 SOUTH SAUNDERS ROAD, SUITE 300, LAKE FOREST, IL, 60045.
Over the last 13 years, insiders at ChemoCentryx Inc have traded over $355,980,520 worth of ChemoCentryx Inc stock and bought 3,166,975 units worth $19,475,662 . The most active insiders traders include Plc Gsk, Rishi Gupta и (International) Ltd Vifor P.... On average, ChemoCentryx Inc executives and independent directors trade stock every 12 days with the average trade being worth of $4,175,785. The most recent stock trade was executed by Susan M Kanaya on 16 August 2022, trading 19,898 units of CCXI stock currently worth $216,092.
ChemoCentryx is a biopharmaceutical company developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. ChemoCentryx's lead drug candidate, avacopan (CCX168), successfully completed a pivotal Phase III trial in ANCA-associated vasculitis and a New Drug Application is under review by the U.S. Food and Drug Administration. Avacopan is also in late stage clinical development for the treatment of severe Hidradenitis Suppurativa and C3 glomerulopathy (C3G). ChemoCentryx also has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer.
ChemoCentryx Inc executives and other stock owners filed with the SEC include: